APA (7th ed.) Citation

Auel, B., Goldschmidt, H., & Möhler, T. (2012). Treatment with thalidomide and cyclophosphamide (TCID) is superior to vincristine (VID) and to vinorelbine (VRID) regimens in patients with refractory or recurrent multiple myeloma. Indian journal of hematology and blood transfusion, 28(2), . https://doi.org/10.1007/s12288-011-0103-1

Chicago Style (17th ed.) Citation

Auel, Britta, Hartmut Goldschmidt, and Thomas Möhler. "Treatment with Thalidomide and Cyclophosphamide (TCID) Is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma." Indian Journal of Hematology and Blood Transfusion 28, no. 2 (2012). https://doi.org/10.1007/s12288-011-0103-1.

MLA (9th ed.) Citation

Auel, Britta, et al. "Treatment with Thalidomide and Cyclophosphamide (TCID) Is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma." Indian Journal of Hematology and Blood Transfusion, vol. 28, no. 2, 2012, https://doi.org/10.1007/s12288-011-0103-1.